Top Markets
Coin of the day
TWi Biotechnology, Inc. TWi Biotechnology, Inc.

TWi Biotechnology, Inc.

6610
Rang in aandelen #17310
TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm,... TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and other uncommon autoimmune skin diseases. TWi Biotechnology has also established a drug development collaboration with Hong Kong Winhealth Pharma Group Co., Limited, targeting the markets of Mainland China, Hong Kong, and Macao. Founded in 2010, the company is headquartered in Taipei, Taiwan.
Aandeelprijs
$1.21
Marktkapitalisatie
$248.41M
Verandering (1 dag)
4.11%
Verandering (1 jaar)
79.12%
Land
TW
Handel TWi Biotechnology, Inc. (6610)

Categorie

Koersgeschiedenis voor TWi Biotechnology, Inc. (6610)
Hoogste slotkoers: $1.18 op 2026-09-01

Laagste slotkoers: $1.95 op 2016-12-01
Koersgeschiedenis van TWi Biotechnology, Inc. van 2016 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) 43.11%
2025 36.47%
2024 -13.49%
2023 13.07%
2022 -19.33%
2021 0.82%
2020 81.49%
2019 -54.47%
2018 -43.81%
2017 -42.56%
2016 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$553.09 37.93%
US
$1.04K 47.72%
NL
$148.49 513.85%
US
$122.21 -10.03%
AU
$757.71 8.20%
CH